Achieving Commercial Success to Benefit Patients Highlighted at the Third Annual Stem Cell Meeting on the Mesa Regen Med

Achieving Commercial Success to Benefit Patients Highlighted at the Third 
Annual Stem Cell Meeting on the Mesa Regen Med Partnering Forum 
Speakers Include Celgene Cellular Therapeutics, GlaxoSmithKline,
Janssen, Baxter, GE Healthcare and the Federal Drug Administration 
WASHINGTON, DC -- (Marketwired) -- 09/24/13 --  The 2013 Stem Cell
Meeting on the Mesa and its Regenerative Medicine Partnering Forum,
the largest gathering of companies, major research institutions and
thought leaders in the sector, will feature a candid exchange in the
plenary session among senior pharmaceutical and biotech execs
regarding the near term prospects for therapeutic breakthroughs. The
program's six panels cover timely business topics such as
reimbursement strategies, navigating regulatory pathways and the
increasing global impact of regenerative medicine. The full agenda
for the meeting is available at:
http://stemcellmeetingonthemesa.com/agenda/. The third annual Regen
Med Partnering Forum will take place October 14 and 15, 2013 at the
Estancia La Jolla Hotel & Spa, La Jolla, California. 
Participation and interest in the field has increased, as evidenced
by the number of large pharmaceutical companies with regenerative
medicine research programs and recent financing deals. This will be
the topic of the program's plenary session, entitled "Curiosity or
Commitment: What type of investment is large pharma and big biotech
really making in regenerative medicine?" Speakers include
senior-level management from GlaxoSmithKline, Celgene Cellular
Therapeutics, Janssen, and Baxter Healthcare Corporation. The session
will be moderated by Greg Lucier of Life Technologies.  
"We are very excited by the potential for new therapeutic
breakthroughs in the field of regenerative medicine that may help
patients challenged by serious and debilitating diseases live longer
and better lives. Celgene Cellular Therapeutics continues to
demonstrate its commitment to bold pursuits in science through
multiple collaborations and funding initiatives," said Perry Karsen,
CEO of Celgene Cellular Therapeutics and Executive Vice President and
COO of Celgene Corporation.  
Additional sessions at the meeting will include:  


 
--  The Global Impact of Regenerative Medicine: Are current healthcare
    systems positioned to maximize the benefit of these technologies?
--  Case Presentation: Cell & Tissue Models in Drug Discovery &
    Development: How Regen Med Companies Help Pharma in 2013
--  Reimbursement in Regenerative Medicine: Will anyone pay for this?
--  Financing Regenerative Medicine & Advanced Therapies: What types
    of investors can and will fund late stage development?
--  Regulatory Challenges & Strategies for Regen Med Companies:
    Insight for navigating the regulatory pathway
--  FDA Oversight of Clinical Trials with Cell Therapies (Featured
    speaker: Celia Witten, Ph.D., M.D., FDA)
--  Understanding & Demonstrating Commercial Viability: How can
    regenerative medicine companies do this better?

  
In addition, the meeting will feature 50+ presentations from the
following companies and academic institutions:
 Aastrom, AlloCure,
Athersys, Avita Medical, BioTime, bluebird bio, BrainStorm Cell
Therapeutics, Capricor, Celsense, Cellular Dynamics, Centre for
Commercialization of Regenerative Medicine (CCRM), Cord Blood
Registry, Cytori, DiscGenics, Fibrocell Science, GlaxoSmithKline,
Histogen, jCyte, Juventas, Lonza, MaxCyte, Medipost, Mesoblast,
Minerva Biotechnologies, Molmed S.p.A., Moores Cancer Center,
Nanofiber Solutions, NeoStem, New York Stem Cell Foundation,
Organogenesis, Organovo, OrthoCyte Corp., Osiris Therapeutics, PCT,
Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics,
RhinoCyte, Roslin Cells, Sanford-Burnham Institute, Sangamo
BioSciences, Shire, SironRX, Stanford Cardiovascular Institute,
Stanford Department of Surgery, StemBioSys, StemCells, Inc., Terumo
BCT, TheraBiologics, TiGenix, University of Utah and ViaCyte 
All six panels and 50+ company presentations taking place during the
Regen Med Partnering Forum will be live-webcast and available for
viewing during the program at
http://stemcellmeetingonthemesa.com/webcast.  
Following the close of the Regen Med Partnering Forum on October 15
is a Public Forum and Reception held at the Sanford Consortium for
Regenerative Medicine. This presentation, which is open to the
general public, features Peter Schultz, Ph.D., Professor of Chemistry
at The Scripps Research Institute and Institute Director of the
Merck-funded California Institute for Biomedical Research (Calibr).
This session will kick-off the Scientific Symposium which will take
place on October 16, 2013 at the Salk Institute for Biological
Studies 
To learn more or to register for the 2013 Stem Cell Meeting on the
Mesa please visit www.stemcellmeetingonthemesa.com. Registration is
complimentary for investors and credentialed members of the media.
Investors and media should contact Laura Parsons or Michelle Linn for
more information. 
About The Alliance for Regenerative Medicine
 The Alliance for
Regenerative Medicine (ARM) is a Washington, DC-based
multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate
access to life-giving advances in regenerative medicine. ARM also
works to increase public understanding of the field and its potential
to transform human healthcare, providing business development and
investor outreach services to support the growth of its member
companies and research organizations. Prior to the formation of ARM
in 2009, there was no advocacy organization operating in Washington,
DC to specifically represent the interests of the companies, research
institutions, investors and patient groups that comprise the entire
regenerative medicine community. Today ARM has more than 140 members
and is the leading global advocacy organization in this field. To
learn more about ARM or to become a member, visit www.alliancerm.org. 
Investor Contact: 
Laura Parsons 
Alliance for Regenerative Medicine 
Phone: 208-841-4334  
Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087